# Initiation of a global consortium to study the progression of age-related macular degeneration: RIMR AMD consortium report # 1

## TL;DR

A global consortium is created to collect and analyze eye imaging data to better understand and treat age-related macular degeneration.

## Contribution

A novel global collaborative framework for AMD research using harmonized multimodal imaging data and cloud-based AI tools.

## Key findings

- The consortium has collected over 100,000 OCT volumes from more than 5,000 subjects across 7 global cohorts.
- A cloud-based infrastructure harmonizes OCT data and clinical metadata for secure AI-driven analysis.
- The dataset spans a wide range of AMD stages with longitudinal follow-up exceeding 15 years for some subjects.

## Abstract

To describe the design and organizational structure of a global collaborative consortium aimed at aggregating longitudinal multimodal imaging data to better understand the progression of age-related macular degeneration (AMD) and facilitate therapeutic development.

The Ryan Initiative for Macular Research (RIMR) AMD Consortium was established as a nonprofit organization, bringing together academic institutions, biopharmaceutical companies, and imaging technology providers. The consortium collects, de-identifies, and harmonizes longitudinal optical coherence tomography (OCT) data, as well as associated clinical metadata, from multiple international clinical centers using a cloud-based infrastructure. Imaging data is converted and stored in DICOM format, and associated clinical data is mapped to the OMOP Common Data Model. All analyses are conducted within a secure cloud environment, supporting both built-in and member-contributed artificial intelligence (AI) tools.

As of the time of reporting, the Consortium has ingested over 100,000 OCT volumes from more than 5,000 subjects across 7 global cohorts spanning 4 continents and 3 major OCT platforms. Based on information provided by the data providers, the dataset encompasses a wide range of AMD stages, from normal aging to late-stage neovascular or atrophic AMD, with longitudinal follow-up extending beyond 15 years for some subjects. A data harmonization pipeline has been established to convert all ingested OCT data to the DICOM standard and is thus ready for automated analysis to gain disease-related insights.

The RIMR AMD Consortium represents a novel model for global collaboration in AMD research, enabling the pooling and analysis of heterogeneous imaging data while addressing privacy, regulatory, and interoperability challenges. This framework may serve as a model for similar initiatives in other ocular diseases.